Showing results (3291-3300 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|January 29, 2002
Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugsFulvio Gualtieri, Dina Manetti, Maria Novella Romanelli, et al.Current Pharmaceutical Design|January 29, 2002
Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophreniaChihiro ItoCurrent Pharmaceutical Design|January 29, 2002
The nitric oxide related therapeutic phenomenon: a challenging taskGiuseppe Cirino, Vincenzo Santagada, Giuseppe CaliendoCurrent Pharmaceutical Design|December 5, 2000
Clinical experience with specific COX-2 inhibitors in arthritisL J CroffordCurrent Pharmaceutical Design|December 5, 2000
Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin researchJ S Thorson, E L Sievers, J Ahlert, et al.Current Pharmaceutical Design|February 15, 2001
Nerve growth factor in neurological and non-neurological diseases: basic findings and emerging pharmacological prospectivesL Aloe, P Tirassa, L Bracci-LaudieroCurrent Pharmaceutical Design|August 13, 2002
The importance of growth hormone (GH) and GH secretagogues for bone mass and densityJohan SvenssonCurrent Pharmaceutical Design|August 13, 2002
Targeting protein kinases for bone disease: discovery and development of Src inhibitorsChester A Metcalf, Marie Rose van Schravendijk, David C Dalgarno, et al.Current Pharmaceutical Design|August 13, 2002
SERMs: evolutionary chemistry, revolutionary biologyChris P MillerCurrent Pharmaceutical Design|August 13, 2002
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisonsRam Ganapathi, Susan A J Vaziri, Masahiro Tabata, et al.Pageof 1,008